Histological characteristics and markers of proliferation and differentiation in rat brain with experimental glioma
Abstract
Background/Aim. The cell line C6 is a continuous cell line of rat glioma and, as a transplantable line, is frequently used for induction into in vivo model of primary brain tumor. It is believed that, pursuant to its histological traits and biological behavior, this experimental tumor corresponds to human anaplastic astrocytoma of grade II/III, which is characterized by proliferative and invasive potency, and marked cell differentiation. The aim of this study was to determine macroscopic analysis of rat brain with implanted tumor during tumorigenesis, histological features of tumor cells of induced brain tumor and markers of proliferation (proliferation cell nuclear antigen – PCNA, cytokeratin – CK 19) and differentiation (glial fibrillary acidic protein – GFAP) in rat brain with implanted tumor. Methods. To determine histological structure of the brain with implanted C6 cells, we used brain sections stained for hematoxylin-eosin or kresyl violet, whereas other sections were immunohistochemically stained for GFAP, CK 19 and PCNA. Results. A statistically significant difference in weights of the left and right brain hemispheres with implanted tumors during tumorigenesis in as soon as 7 days from the day of inducing tumors was revealed. The tumor was of cellular type, with distinct pleomorphism of cells and frequent hyperchromasia of the nucleus. Immunohistochemical staining for PCNA revealed a significant number of positive cells on the days 7, 14 and 21 day following the implantation of C6 cells. CK 19 positive cells were present in both brain hemispheres, and numerous GFAP positive astrocytes were found around the puncture lesion. Conclusions. Within the experimental conditions of the present research, C6 glioma did not demonstrate any relevant deviations concerning development, clinical symptomatology and macroscopic anatomy relative to those already described in the literature.
References
Benda P, Lighthody J, Sato G, Levine L, Sweet W. Differentiated rat glial cell strain in tissue culture. Science 1968; 161(3839): 370−1.
Bullard DE, Schold SC, Bigner SH, Bigner DD. Growth and che-motherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 1981; 40(4): 410−27.
Bissell MG, Rubinstein LJ, Bignami A, Herman MM. Characteristics of the rat C-6 glioma maintained in organ culture systems. Production of glial fibrillary acidic protein in the absence of gliofibrillogenesis. Brain Res 1974; 82(1): 77−89.
Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987; 326(6112): 515−7.
Garcia R, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. Am J Pathol 1989; 134(4): 733−9.
Koch PJ, Roop DR. The role of keratins in epidermal develop-ment and homeostasis-going beyond the obvious. J Invest Dermatol 2004; 123(5): 10−1.
Rutka JT, Smith SL. Transfection of human astrocytoma cells with glial fibrillary acidic protein complementary DNA analysis of expression proliferation and tumorogenticity. Cancer Res 1993; 53(15): 3624−31.
Perentes E, Rubinstein LJ. Recent applications of immunoperox-idase histochemistry in human neuro-oncology. An update. Arch Pathol Lab Med 1987; 111(9): 796−812.
Kleihues P, Burger PC, Scheithauer BW. The new WHO classifica-tion of brain tumours. Brain Pathol 1993; 3(3): 255−68.
Chicoine MR, Silbergeld DL. Invading C6 glioma cells maintain-ing tumorigenicity. J Neurosurgery 1995; 83(4): 665−71.
Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a compari-son between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29(4): 577−80.
Black PM. Brain tumors. Part 1. N Engl J Med 1991; 324(21): 1471−6.
Hiesiger EM, Voorhies RM, Basler GA, Lipschutz LE, Posner JB, Shapiro WR. Opening the blood-brain and blood-tumor bar-riers in experimental rat brain tumors: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann Neurol 1986; 19(1): 50−9.
Nomura Y, Kitamura Y. Inducible nitric oxide synthase in glial cells. Neurosci Res 1993; 18(2): 103−7.
Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 1998; 36(1): 91−102.
Auer RN, del Maestro RF, Anderson R. A simple and reproducible experimental in vivo glioma model. Can J Neurol Sci 1981; 8(4): 325−31.
Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109(1): 93−108.
Fu Y, Du J, Yang R, Yin L, Liang A. Potential adenovirus-mediated gene therapy of glioma cancer. Biotechnol Lett 2010; 32(1): 11−8.
Chekhonin VP, Baklaushev VP, Yusubalieva GM, Pavlov KA, Uk-hova OV, Gurina OI. Modeling and immunohistochemical anal-ysis of C6 glioma in vivo. Bull Exp Biol Med 2007; 143(4): 501−9.
Yusubalieva GM, Baklaushev VP, Gurina OI, Tsitrin EB, Chekhonin VP. Immunochemical analysis of glial fibrillary acidic protein as a tool to assess astroglial reaction in experimental C6 glioma. Bull Exp Biol Med 2010; 149(1): 125−30.
Chekhonin VP, Baklaushev VP, Yusubalieva GM, Gurina OI. Tar-geted transport of 125I-labeled antibody to GFAP and AMVB1 in an experimental rat model of C6 glioma. Neu-roimmune Pharmacol 2009; 4(1): 28−34.
Vince GH, Bendszus M, Schweitzer T, Goldbrunner RH, Hildebrandt S, Tilgner J, et al. Spontaneous regression of experimental gli-omas: an immunohistochemical and MRI study of the C6 gli-oma spheroid implantation model. Exp Neurol 2004; 190(2): 478−85.